retatrutide eli lilly press release 2024 2025 Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide Isn't the Endgame. Brenipatide

Individual factors such as baseline gut sensitivity, concurrent medications (especially metformin, which can independently cause diarrhea), and pre-existing conditions like irritable bowel syndrome significantly influence whether diarrhea develops and its severity

Advances in formulation, such as mucoadhesive systems, have helped prolong drug contact, optimize concentration gradients, and improve bioavailability

VenierNAYamamotoTSugarLMAdomatHFleshnerNEKlotzLHet al

For women with PCOS or insulin resistance, GLP-1s may help restore ovulation

In the first reaction, L-cysteine and L-glutamate are combined by the action of the enzyme called glutamate-cysteine ligase (GSHl, 6.3.2.2), generating the intermediate y-glutamylcysteine (-EC)

One of the most common reasons patients discontinue GLP-1 RA treatment is due to gastrointestinal side effects, which could be attributed to the markedly high GLP-1 RA levels